[2021] ALK Positive Lung Cancer Treatment Market Size Estimation, Future Growth Insights, Share Analysis, Key Profile, Dynamics and Business Overview By 2026

SEATTLE, April 12, 2021, (PHARMIWEB) — ALK Positive Lung Cancer Treatment Market – Insights

Anaplastic Lymphoma Kinase (ALK) positive lung cancer is caused due to mutation of ALK, a gene that aids introduction of proteins. In the mutation, fusion of two genes called as ALK and Echinoderm Microtubule-associated protein Like 4 (EML4) leads to gene rearrangement. The ALK gene fusion was first reported in 2007, in non-small cell lung cancer (NSCLC) patients.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/2201

Increasing R&D of new drugs to augment growth of the market

Increasing focus of market players in R&D and approval of new drugs is expected to boost growth of the global ALK positive lung cancer treatment market. For instance, in August 2018, China National Drug Administration (CNDA) approved Alecensa (alectinib) of F. Hoffmann-La Roche Ltd. for the treatment of ALK-positive lung cancer. Moreover, CNDA also granted marketing authorization for Alecensa (alectinib), as monotherapy treatment for patients with ALK-positive and advanced non-small cell lung cancer (NSCLC).

Increasing resistance to drugs to hinder growth of the market

Increasing resistance to drugs is expected to hamper growth of the ALK positive lung cancer treatment market. For instance, according to an Oncology Live February 2018 report, major challenge in drug development is rapid growth in resistance, which is responsible for slow patient recovery from disease. Moreover, according to an article published in Cancers journal, in August 2017, the mechanisms for resistance in drugs is tyrosine kinase mutations and Epidermal Growth Factor Receptor (EGFR) activation. These bypass mechanisms of resistance are aggravating tumor cells.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2201

North America is expected to witness significant growth in the market

Increasing number of clinical trials is expected to boost growth of the market in North America. For instance, TP Therapeutics, Inc. is undergoing clinical trial for TPX-0005 drug for the treatment of ALK mutations. The study is expected to complete in December 2021.

Increasing prevalence of lung cancer is expected to propel growth of the market in Asia Pacific.  For instance, according to an article published in Eastern Journal of medical Sciences 2017, lung cancer contributes around 6.8% of all cancers in India, representing the significant burden of lung cancer on the country, which is contributing towards cancer morbidity and mortality.

ALK Positive Lung Cancer Treatment Market: Competitive Landscape

Major players operating in the ALK positive lung cancer treatment market include, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, and TP Therapeutics, Inc.

*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2201

ALK Positive Lung Cancer Treatment Market – Taxonomy

• By Drug
  • Crizotinib
  • Alectinib
  • Brigatinib
  • Ceritinib
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Clinics
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837